Research progress of immunocytes and immunologic factors related to acute exacerbation of chronic obstructive pulmonary disease

Li Rui; Xiao Li

doi:10.11855/j.issn.0577-7402.1493.2023.0413

您当前的位置：

首页 >

文章列表页 >

Research progress of immunocytes and immunologic factors related to acute exacerbation of chronic obstructive pulmonary disease

Review | 更新时间：2023-12-13

- Research progress of immunocytes and immunologic factors related to acute exacerbation of chronic obstructive pulmonary disease
- Medical Journal of Chinese People′s Liberation Army Vol. 48, Issue 11, Pages: 1353-1358(2023)
- 作者机构：
  
  1.河北北方学院研究生学院，河北张家口 075000
  2.解放军总医院第八医学中心呼吸与危重症医学部研究所/北京市器官移植与免疫调节重点实验室，北京 100091
- 作者简介：
  
  E-mail: xiaolilab309@163.com
- 基金信息：
  
  the Capital`s Fund for Health Improvement and Independent Innovation Research(2022-2-5092)
- DOI：10.11855/j.issn.0577-7402.1493.2023.0413
  CLC：
扫描看全文
李蕊, 肖漓. 慢性阻塞性肺疾病急性加重相关的免疫细胞及因子研究进展[J]. 解放军医学杂志, 2023, 48(11): 1353-1358.

Li Rui,Xiao Li.Research progress of immunocytes and immunologic factors related to acute exacerbation of chronic obstructive pulmonary disease[J].Medical Journal of Chinese People′s Liberation Army,2023,48(11):1353-1358.
李蕊, 肖漓. 慢性阻塞性肺疾病急性加重相关的免疫细胞及因子研究进展[J]. 解放军医学杂志, 2023, 48(11): 1353-1358. DOI： 10.11855/j.issn.0577-7402.1493.2023.0413.

Li Rui,Xiao Li.Research progress of immunocytes and immunologic factors related to acute exacerbation of chronic obstructive pulmonary disease[J].Medical Journal of Chinese People′s Liberation Army,2023,48(11):1353-1358. DOI： 10.11855/j.issn.0577-7402.1493.2023.0413.

摘要

慢性阻塞性肺疾病(COPD)是呼吸系统的多发病和常见病，且一直存在早期诊断率低、治疗依从性低、治疗规范性低等问题。临床实践显示，COPD的异质性是其治疗困难的原因之一。近年来逐渐认识到COPD的发生发展与机体免疫状态密切相关，多项研究试图寻找特异性强、灵敏度高的细胞与分子生物标记物，以早期诊断COPD急性加重并进行亚型区分，为COPD患者提供个体化的诊疗策略。本文综述近年来与不同表型COPD及疾病进展密切相关的免疫细胞及因子作为生物标志物的研究进展，旨在为COPD的诊断与治疗研究提供参考。

Abstract

Chronic obstructive pulmonary disease (COPD) is a frequent and common disease of the respiratory system. The problem of low early diagnosis rate, low treatment compliance, and low treatment standardization has persisted in the diagnosis and treatment of COPD. Heterogeneity found in clinical practice is one of the reasons why COPD is difficult to treat. In recent years, it has been gradually recognized that the occurrence and development of COPD are closely related to the immune state of the body. At present, it become one of the hot spots in clinical and basic research that searching for specific and sensitive cell and molecular biomarkers to early diagnose acute exacerbation and subtype differentiation of COPD, which ultimately provide individual diagnosis and treatment strategies for COPD patients. This review focuses on the research progress of immunocytes and immunologic factors as biomarkers to different phenotypes and progression of COPD in recent years, providing a reference for the research on diagnosis and treatment of COPD.

关键词

慢性阻塞性肺疾病急性加重期免疫细胞免疫因子生物标志物

Keywords

acute exacerbation of chronic obstructive pulmonary disease (AECOPD)immunocyteimmunologic factorbiomarker

references

Venkatesan P. GOLD report: 2022 update[J]. Lancet Respir Med, 2022, 10(2): e20.

Agustí A, Melén E, DeMeo DL, et al. Pathogenesis of chronic obstructive pulmonary disease: understanding the contributions of gene-environment interactions across the lifespan[J]. Lancet Respir Med, 2022, 10(5): 512-524.

Yang IA, Jenkins CR, Salvi SS. Chronic obstructive pulmonary disease in never-smokers: risk factors, pathogenesis, and implications for prevention and treatment[J]. Lancet Respir Med, 2022, 10(5): 497-511.

Agustí A, Vogelmeier C, Faner R. COPD 2020: changes and challenges[J]. Am J Physiol Lung Cell Mol Physiol, 2020, 319(5): L879-L883.

Chronic Obstructive Pulmonary Disease Group of Chinese Thoracic Society, Chronic Obstructive Pulmonary Disease Committee of Chinese Association of Chest Physician. Guidelines for the diagnosis and management of chronic obstructive pulmonary disease (revised version 2021)[J]. Chin J Tuberc Respir Dis, 2021, 44(3): 170-205.

中华医学会呼吸病学分会慢性阻塞性肺疾病学组, 中国医师协会呼吸医师分会慢性阻塞性肺疾病工作委员会. 慢性阻塞性肺疾病诊治指南(2021年修订版)[J]. 中华结核和呼吸杂志, 2021, 44(3): 170-205.

Mirza S, Benzo R. Chronic obstructive pulmonary disease phenotypes: implications for care[J]. Mayo Clin Proc, 2017, 92(7): 1104-1112.

Szalontai K, Gémes N, Furák J, et al. Chronic obstructive pulmonary disease: epidemiology, biomarkers, and paving the way to lung cancer[J]. J Clin Med, 2021, 10(13): 2889.

Yip KP, Stockley RA, Sapey E. Catching "early" COPD - the diagnostic conundrum[J]. Int J Chron Obstruct Pulmon Dis, 2021, 16: 957-968.

Jasper AE, McIver WJ, Sapey E, et al. Understanding the role of neutrophils in chronic inflammatory airway disease[J]. F1000Res, 2019, 8: F1000 Faculty Rev-557.

Dicker AJ, Crichton ML, Pumphrey EG, et al. Neutrophil extracellular traps are associated with disease severity and microbiota diversity in patients with chronic obstructive pulmonary disease[J]. J Allergy Clin Immunol, 2018, 141(1): 117-127.

Hassani M, van Staveren S, van Grinsven E, et al. Characterization of the phenotype of human eosinophils and their progenitors in the bone marrow of healthy individuals[J]. Haematologica, 2020, 105(2): e52-e56.

Whittaker HR, Müllerova H, Jarvis D, et al. Inhaled corticosteroids, blood eosinophils, and FEV1 decline in patients with COPD in a large UK primary health care setting[J]. Int J Chron Obstruct Pulmon Dis, 2019, 14: 1063-1073.

Jo YS, Moon JY, Park YB, et al. Longitudinal changes in forced expiratory volume in 1 s in patients with eosinophilic chronic obstructive pulmonary disease[J]. BMC Pulm Med, 2022, 22(1): 91.

Albanna A, Almuyidi FM, Beitar NF, et al. Clinical characteristics and outcome related to blood eosinophilic chronic obstructive pulmonary disease (COPD) patients[J]. Cureus, 2022, 14(8): e27998.

Hastie AT, Martinez FJ, Curtis JL, et al. Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort[J]. Lancet Respir Med, 2017, 5(12): 956-967.

Pignatti P, Visca D, Cherubino F, et al. Do blood eosinophils strictly reflect airway inflammation in COPD? Comparison with asthmatic patients[J]. Respir Res, 2019, 20(1): 145.

MacDonald MI, Osadnik CR, Bulfin L, et al. Low and high blood eosinophil counts as biomarkers in hospitalized acute exacerbations of COPD[J]. Chest, 2019, 156(1): 92-100.

Bafadhel M, Pavord ID, Russell REK. Eosinophils in COPD: just another biomarker? [J]. Lancet Respir Med, 2017, 5(9): 747-759.

Narendra DK, Hanania NA. Targeting IL-5 in COPD[J]. Int J Chron Obstruct Pulmon Dis, 2019, 14: 1045-1051.

Zhang C, Wang Y, Zhang M, et al. Monoclonal antibodies targeting IL-5 or IL-5Rα in eosinophilic chronic obstructive pulmonary disease: a systematic review and meta-Analysis[J]. Front Pharmacol, 2021, 12: 754268.

Liew FY, Girard JP, Turnquist HR. Interleukin-33 in health and disease[J]. Nat Rev Immunol, 2016, 16(11): 676-689.

Cayrol C, Girard JP. Interleukin-33 (IL-33): A nuclear cytokine from the IL-1 family[J]. Immunol Rev, 2018, 281(1): 154-168.

Dwyer GK, D'Cruz LM, Turnquist HR. Emerging functions of IL-33 in homeostasis and immunity[J]. Annu Rev Immunol, 2022, 40: 15-43.

Li Q, Hu Y, Chen Y, et al. IL-33 induces production of autoantibody against autologous respiratory epithelial cells: a potential mechanism for the pathogenesis of COPD[J]. Immunology, 2019, 157(2): 137-150.

Altman MC, Lai Y, Nolin JD, et al. Airway epithelium-shifted mast cell infiltration regulates asthmatic inflammation via IL-33 signaling[J]. J Clin Invest, 2019, 129(11): 4979-4991.

Rabe KF, Celli BR, Wechsler ME, et al. Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial[J]. Lancet Respir Med, 2021, 9(11): 1288-1298.

Silva BSA, Lira FS, Ramos D, et al. Severity of COPD and its relationship with IL-10[J]. Cytokine, 2018, 106: 95-100.

Song J, Zeng M, Wang H, et al. Distinct effects of asthma and COPD comorbidity on disease expression and outcome in patients with COVID-19[J]. Allergy, 2021, 76(2): 483-496.

Wei B, Tian T, Liu YG. IL-10 Combined with NGAL has diagnostic value for AECOPD combined with AKI[J]. Int J Chron Obstruct Pulmon Dis, 2020, 15: 637-644.

Tang J, Ramis-Cabrer D, Curull V, et al. Immune cell subtypes and cytokines in lung tumor microenvironment: influence of COPD[J]. Cancers (Basel), 2020, 12(5): 1217.

Hansen BT, Maschkowitz G, Podschun R, et al. The kinocidin interleukin-26 shows immediate antimicrobial effects even to multi-resistant isolates[J]. Front Microbiol, 2021, 12: 757215.

Magnusson JM, Ericson P, Tengvall S, et al. Involvement of IL-26 in bronchiolitis obliterans syndrome but not in acute rejection after lung transplantation[J]. Respir Res, 2022, 23(1): 108.

Che KF, Tengvall S, Lindén A. Interleukin-26 in host defense and inflammatory disorders of the airways[J]. Cytokine Growth Factor Rev, 2021, 57: 1-10.

Che KF, Paulsson M, Piersiala K, et al. Complex involvement of interleukin-26 in bacterial lung infection[J]. Front Immunol, 2021, 12: 761317.

Cardenas EI, Che KF, Konradsen JR, et al. IL-26 in asthma and COPD[J]. Expert Rev Respir Med, 2022, 16(3): 293-301.

Luan YY, Yin CH, Yao YM. Update advances on C-reactive protein in COVID-19 and other viral infections[J]. Front Immunol, 2021, 12: 720363.

Stolz D, Christ-Crain M, Gencay MM, et al. Diagnostic value of signs, symptoms and laboratory values in lower respiratory tract infection[J]. Swiss Med Wkly, 2006, 136(27-28): 434-440.

Prins HJ, Duijkers R, van der Valk P, et al. CRP-guided antibiotic treatment in acute exacerbations of COPD in hospital admissions[J]. Eur Respir J, 2019, 53(5): 1802014.

Daniels JM, Schoorl M, Snijders D, et al. Procalcitonin vs C-reactive protein as predictive markers of response to antibiotic therapy in acute exacerbations of COPD[J]. Chest, 2010, 138(5): 1108-1115.

Huang L, Wang J, Gu X, et al. Procalcitonin-guided initiation of antibiotics in AECOPD inpatients: study protocol for a multicenter randomised controlled trial[J]. BMJ Open, 2021, 11(8): e049515.

Ingebrigtsen TS, Marott JL, Rode L, et al. Fibrinogen and α1-antitrypsin in COPD exacerbations[J]. Thorax, 2015, 70(11): 1014-1021.

Hyun DG, Lee JH, Oh YM, et al. Association of plasma fibrinogen concentrations and blood eosinophil counts with clinical phenotypes of COPD[J]. Int J Tuberc Lung Dis, 2019, 23(9): 1035-1041.

Serban KA, Pratte KA, Bowler RP. Protein biomarkers for COPD outcomes[J]. Chest, 2021, 159(6): 2244-2253.

Balbi B, Sangiorgi C, Gnemmi I, et al. Bacterial load and inflammatory response in sputum of alpha-1 antitrypsin deficiency patients with COPD[J]. Int J Chron Obstruct Pulmon Dis, 2019, 14: 1879-1893.

Topic A, Milovanovic V, Lazic Z, et al. Oxidized alpha-1-antitrypsin as a potential biomarker associated with onset and severity of chronic obstructive pulmonary disease in adult population[J]. COPD, 2018, 15(5): 472-478.

Views

下载量

CSCD

CNKI被引量

Alert me when the article has been cited

提交

Tools

Publicity Resources

Research progress of small nucleolar RNA host gene 17 involved in cancer process

Prevention and treatment of combat injury and acute renal injury related to special working environment

Evaluation of age-related changes of early kidney injury markers in plasma of septic rats

Circular RNAs: biogenesis, functions, and roles in cardiovascular diseases

Related Author

No data

Related Institution

Institute of Respiratory and Critical Care Medicine/Beijing Key Laboratory of Organ Transplantation and Immunology Regulatory, the 8th Medical Center of Chinese PLA General Hospital

College of Clinical Medicine, Ningxia Medical University

The Second Department of General Surgery, Gansu Provincial People's Hospital

Gansu Key Laboratory of Molecular Diagnostics and Precision Medicine for Surgical Oncology/Gansu Research Center of Prevention and Control Project for Digestive Oncology, the First School of Clinical Medicine, Lanzhou University

Department of Nephrology,Chinese PLA General Hospital/Chinese PLA Institute of Nephrology/State Key Laboratory of Kidney Diseases/National Clinical Research Center for Kidney Diseases

⁰